Novel Mouse Model and Organoid Program Advance Drug Discovery for Adult Granulosa Cell Tumors
Key Insights
MD Anderson researchers have established the first genetically inducible mouse model for adult-type granulosa cell tumor (search) (AGCT (search)), utilizing an engineered FOXL2 (search) allele to enhance drug development capabilities.
Scientists discovered that glucocorticoids (search) stimulate AGCT (search) cell growth specifically in the presence of FOXL2 (search) mutations, revealing a significant pharmacogenetic relationship.
The research team has implemented an organoid derivation program for AGCT (search) patients undergoing surgery, enabling high-throughput drug screening and personalized treatment exploration.
Researchers at The University of Texas MD Anderson Cancer Center have achieved significant breakthroughs in developing new experimental models for adult-type granulosa cell tumor (search) (AGCT (search)) of the ovary, potentially accelerating the path toward novel therapeutic interventions.
Groundbreaking Mouse Model Development
In a major advancement for AGCT (search) research, scientists have created the first genetically inducible mouse model of the disease. "We think that [this model] is going to really move us forward, as far as having a high-fidelity animal model for the first time, [which] will let us do kinds of investigations that weren't really possible before," explains R. Tyler Hillman, MD, PhD, assistant professor in the Department of Gynecologic Oncology and Reproductive Medicine.
Key Discovery in Glucocorticoid Response
Through their innovative organoid derivation program, researchers have uncovered a crucial relationship between glucocorticoids (search) and FOXL2 (search) mutations. The team demonstrated that glucocorticoids can stimulate AGCT (search) cell growth, but only in cells carrying FOXL2 mutations, indicating a clear pharmacogenetic effect. This finding was published in Cancer Research in 2024, showing that glucocorticoids exhibited nanomolar EC50 activity in KGN-FOXL2WT/C402G cells while showing no effect in KGN-FOXL2–/– cells.
Innovative Organoid Program
MD Anderson has established a pioneering organoid derivation program for AGCT (search) patients undergoing surgery. This program enables researchers to collect and analyze tumor samples for drug testing and experimental purposes, including high-throughput screening. The approach has already yielded valuable insights into disease mechanisms and potential therapeutic targets.
Future Therapeutic Directions
Dr. Hillman's laboratory is pursuing two primary research directions: identifying new drug candidates for clinical trials and understanding the mechanistic relationship between FOXL2 (search) mutations and tumor development. Current investigations are focused on modulating glucocorticoid receptor (search) signaling, potentially through single-agent or combination therapy approaches with existing chemotherapeutic regimens.
The convergence of these research initiatives - the mouse model, organoid program, and mechanistic studies - represents a significant step forward in AGCT (search) research, potentially opening new avenues for targeted therapy development in this rare ovarian cancer.